Skip to main content

Exact Sciences Value Stock - Dividend - Research Selection

Exact sciences

ISIN: US30063P1057 , WKN: 590273

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term

2025-09-15
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Exact Sciences Launches Cancerguard MCED Blood Test, Stock Climbs

2025-09-12
EXAS introduces Cancerguard, a blood test that detects more than 50 cancers, sending shares up after its U.S. debut.

Exact Sciences price target raised to $85 from $65 at Craig-Hallum

2025-09-12
Craig-Hallum raised the firm’s price target on Exact Sciences (EXAS) to $85 from $65 and keeps a Buy rating on the shares. The firm would be a buyer of Exact Sciences. With the Freenome deal in place and Shield V2 data out, Craig-Hallum thinks the Street will begin to focus on execution. With a stable of incremental near-term revenue growth drivers, prospects for continued EBITDA margin expansion, substantially improving cash flow, and potential upside to estimates, the stock could break out of

More Blood Tests for Cancer Hit the Market

2025-09-11
The tests look for bits of altered DNA that cancer cells shed into the bloodstream. The screening technology holds hope of finding cancers early, when they might be cured.

Why NeoGenomics (NEO) Shares Are Falling Today

2025-09-10
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 5.1% in the afternoon session after a key competitor, Exact Sciences, announced the launch of a new multi-cancer early detection blood test.

Why Natera (NTRA) Shares Are Falling Today

2025-09-10
Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.1% in the afternoon session after a key competitor, Exact Sciences, announced the launch of a new multi-cancer early detection blood test.

Should You Continue to Hold EXAS Stock in Your Portfolio?

2025-09-10
Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.

Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test

2025-09-10
MADISON, Wis., September 10, 2025--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. Cancerguard is the first MCED test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when trea

Exact Sciences Corporation (EXAS) Presents At Baird 2025 Global Healthcare Conference

2025-09-09
The following slide deck was published by Exact Sciences Corporation in conjunction with this event.

Exact Sciences Corporation (EXAS) Presents At Baird 2025 Global Healthcare Conference (Transcript)

2025-09-09
Discover Exact Sciences' latest innovations in cancer diagnostics, Cologuard brand growth,